Ultraschall Med 2012; 33(S 01): S48-S56
DOI: 10.1055/s-0032-1312899
Supplement
© Georg Thieme Verlag KG Stuttgart · New York

The Role of CEUS in the Characterization of Hepatocellular Nodules Detected During the US Surveillance Program – Current Practices in Europe

Die Bedeutung von CEUS bei der Charakterisierung von hepatozellulären Knoten, die beim Überwachungsprogramm der USA entdeckt wurden – aktuelle Praxis in Europa
E. Quaia
1   Department of Radiology, Cattinara Hospital, University of Trieste (Italy)
,
A. Lorusso
1   Department of Radiology, Cattinara Hospital, University of Trieste (Italy)
,
G. Grisi
2   Department of Economic, Business, Statistical and Mathematical Sciences, University of Trieste (Italy)
,
F. Stacul
1   Department of Radiology, Cattinara Hospital, University of Trieste (Italy)
,
M. A. Cova
1   Department of Radiology, Cattinara Hospital, University of Trieste (Italy)
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
21. Juni 2012 (online)

Abstract

The basic pathological feature for the differential diagnosis between hepatocellular carcinoma (HCC) and non-malignant hepatocellular nodules in cirrhotic patients detected during ultrasound (US) is the vascular supply to the nodule. Computed tomography (CT) and magnetic resonance imaging (MRI) are considered reference imaging techniques for depicting hepatocellular nodule vascularity in the noninvasive diagnosis of HCC. Contrast-enhanced US (CEUS) improves the diagnostic performance of unenhanced US in the diagnosis of HCC, giving an overall diagnostic accuracy that is similar to that of CT, even for nodules smaller than 2 cm. An additional diagnostic feature of CEUS relative to CT is the possibility to visualize contrast wash-in to hepatic nodules during the arterial phase and contrast washout during the portal venous and late phases. Sensitivity for the diagnosis of HCC with combined assessment of CEUS and CT is higher than for separate assessments of CEUS and CT due to the reduction of false-negative findings. CEUS represents a competitive imaging method from an economic point of view, and is an effective imaging tool for assessing the therapeutic outcome after surgery, ablation therapy, and transarterial chemoembolization (TACE).

Zusammenfassung

Bei der Differenzialdiagnose von hepatozellulären Karzinomen (HCC) und benignen hepatozellulären Knoten bei Zirrhose-Patienten ist das im Ultraschall (US) festzustellende, wesentliche pathologische Merkmal die Gefäßversorgung des Knotens. Die Computertomografie (CT) und die Magnetresonanztomografie (MRT) gelten als bildgebende Referenzmethoden in der nicht invasiven Diagnostik des HCC, um die Vaskularisierung des hepatozellulären Knotens darzustellen. Der kontrastverstärkte US (CEUS) verbessert die diagnostische Aussage des nicht kontrastverstärkten US bei der Diagnose eines HCC, wobei selbst für Knoten unter 2 cm eine diagnostische Genauigkeit erreicht wird, die der einer CT entspricht. Eine weitere diagnostische Leistung des CEUS im Vergleich zur CT ist durch die Möglichkeit gegeben, das Wash-in des Kontrastmittels in die hepatischen Knoten während der arteriellen Phase und das Wash-out des Kontrastmittels während der portalen venösen und späten Phase darzustellen. Die Sensitivität für die Diagnose eines HCC bei kombinierter Bewertung mittels CEUS und CT ist höher, als bei voneinander getrennten Auswertungen beider Methoden, da dadurch falsch negative Befunde verringert werden. Vom ökonomischen Standpunkt her gesehen ist der CEUS ein konkurrenzfähiges bildgebendes Verfahren, ebenso ist er ein effektives bildgebendes Verfahren, um das therapeutische Ansprechen nach Operation, Ablationstherapie oder transarterielle Chemoembolisierung (TACE) zu bewerten.

 
  • References

  • 1 Zoli M, Magalotti D, Bianchi G et al. Efficacy of a surveillance program for early detection of hepatocellular carcinoma. Cancer 1996; 78: 977-985
  • 2 Kojiro M, Roskams T. Early hepatocellular carcinoma and dysplastic nodules. Semin Liver Dis 2005; 25: 133-142
  • 3 Sakamoto M, Hirohashi S, Shimosato Y. Early stages of multistep hepatocarcinogenesis: adenomatous hyperplasia and early hepatocellular carcinoma. Hum Pathol 1991; 22: 172-178
  • 4 Efremidis SC, Hytiroglou P. The multistep process of hepatocarcinogenesis in cirrhosis with imaging correlation. Eur Radiol 2002; 12: 753-764
  • 5 Bruix J, Sherman M, Llovet JM et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-430
  • 6 Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236
  • 7 Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699
  • 8 Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022
  • 9 Vilana R, Forner A, Bianchi L et al. Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound. Hepatology 2010; 51: 2020-2029
  • 10 Chen LD, Xu HX, Xie XY et al. Intrahepatic cholangiocarcinoma and hepatocellular carcinoma: differential diagnosis with contrast-enhanced ultrasound. Eur Radiol 2010; 20: 743-753
  • 11 Pomfret EA, Washburn K, Wald C et al. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the united states. Liver Transpl 2010; 16: 262-278
  • 12 Claudon M, Cosgrove D, Albrecht T et al. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) – update 2008. Ultraschall in Med 2008; 29: 28-44
  • 13 Clinical Practice Guidelines for Hepatocellular Carcinoma – The Japan Society of Hepatology 2009 update. Diagnosis and surveillance. Hepatology Research 2010; 40: 16-47
  • 14 Quaia E, D’Onofrio M, Cabassa P et al. The Diagnostic Value of Hepatocellular Nodule Vascularity after Sulfur Hexafluoride – filled Microbubble Injection in Patients with Liver Cirrhosis: Analysis of Diagnostic Performance and Confidence in Malignancy Characterization. Am Journal Roentgenology 2007; 189: 1474-1483
  • 15 Jang HJ, Kim TK, Burns PN et al. Enhancement patterns of hepatocellular carcinoma at contrast-enhanced US: comparison with histologic differentiation. Radiology 2007; 244: 898-906
  • 16 Quaia E, Alaimo V, Baratella E et al. The added diagnostic value of 64-row multidetector CT combined with contrast-enhanced US in the evaluation of hepatocellular nodule vascularity: implications in the diagnosis of malignancy in patients with liver cirrhosis. Eur Radiol 2009; 19: 651-663
  • 17 Sangiovanni A, Manini MA, Iavarone M et al. The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut 2010; 59: 638-644
  • 18 Ikeda K, Saitoh S, Koida I et al. Diagnosis and follow-up of small hepatocellular carcinoma with selective intraarterial digital subtraction angiography. Hepatology 1993; 17: 1003
  • 19 Chen RC, Wang CK, Wang CS et al. Depiction of vasculature in small hepatocellular carcinoma, and dysplastic nodules: evaluation with carbondioxide ultrasonography and angiography. Acta Radiol 2002; 43: 66-70
  • 20 Luca A, Caruso S, Milazzo M et al. Multidetector-row computed tomography (MDCT) for the diagnosis of hepatocellular carcinoma in cirrhotic candidates for liver transplantation: prevalence of radiological vascular patterns and histological correlation with liver explants. Eur Radiol 2010; 20: 898-907
  • 21 Furlan A, Marin D, Cabassa P et al. Enhancement pattern of small hepatocellular carcinoma (HCC) at contrast-enhanced US (CEUS), MDCT, and MRI: Intermodality agreement and comparison of diagnostic sensitivity between 2005 and 2010 American Association for the Study of Liver Diseases (AASLD) guidelines. Eur J Radiol 2011; DOI: 10.1016/j.ejrad.2011.07.010.
  • 22 Forner A, Vilana R, Ayuso C et al. Diagnosis of Hepatic Nodules 20 mm or Smaller in cirrhosis: Prospective Validation of the Noninvasive Diagnostic Criteria for Hepatocellular Carcinoma. Hepatology 2008; 47: 97-104
  • 23 Lencioni R. Locoregional treatment of hepatocellular carcinoma. Hepatology 2010; 52: 762-773
  • 24 Numata K, Morimoto M, Ogura T et al. Ablation therapy guided by contrast-enhanced sonography with Sonazoid for hepatocellular carcinoma lesions not detected by conventional sonography. J Ultrasound Med 2008; 27: 395-406
  • 25 Maruyama H, Takahashi M, Ishibashi H et al. Ultrasound-guided treatments under low acoustic power contrast harmonic imaging for hepatocellular carcinomas undetected by B-mode ultrasonography. Liver Int 2009; 29: 708-714
  • 26 Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52-60
  • 27 Minami Y, Kudo M. Review of dynamic contrast-enhanced ultrasound guidance in ablation therapy for hepatocellular carcinoma. World J Gastroenterol 2011; 17: 4952-4959
  • 28 Lu MD, Yu XL, Li AH et al. Comparison of contrast enhanced ultrasound and contrast enhanced CT or MRI in monitoring percutaneous thermal ablation procedure in patients with hepatocellular carcinoma: a multi-center study in China. Ultrasound Med Biol 2007; 33: 1736-1749
  • 29 Minami Y, Kudo M. Radiofrequency ablation of hepatocellular carcinoma: Current status. World J Radiol 2010; 28: 417-424